SCHEMBL19783373

SCHEMBL19783373

Cc1cc(OCc2ccccc2)cc2sc(Br)nc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.47
MAOB P27338 3/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA7 P43166 1/20 0.43
CA9 Q16790 1/20 0.43
ALOX5 P09917 1/20 0.42
SCD O00767 1/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
HTT P42858 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
MAPT P10636 1/20 0.41
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
STAT3 P40763 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MAOA P21397 1/20 0.39
PDGFRB P09619 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20305432 0.84 PDGFRB (0.48) CYP3A4MAOBCA12CA1CA2
SCHEMBL19617648 0.80 CYP3A4 (0.46) CYP3A4MAOBCA12CA1CA2
SCHEMBL19783647 0.80 MAPT (0.44) CYP3A4CA12CA1CA2CA7
SCHEMBL16151069 0.76 CYP3A4 (0.72) CYP3A4MAOBCA12CA1CA2
SCHEMBL30189754 0.76 HSD17B10 (0.37) CYP3A4NPC1RAB9AHTTL3MBTL1
SCHEMBL19783059 0.76 HSD17B10 (0.37) CYP3A4NPC1RAB9AHTTL3MBTL1
SCHEMBL3629799 0.76 MAOB (0.56) MAOBALOX5NPC1RAB9AL3MBTL1
SCHEMBL15287235 0.75 MAOB (0.54) MAOBALOX5NPC1RAB9AL3MBTL1
SCHEMBL19782939 0.75 F2RL3 (0.43) CYP3A4NPC1RAB9AL3MBTL1MAPT
SCHEMBL30187624 0.73 F2RL3 (0.69) CYP3A4SCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109689647-B Bicyclic heteroaryl substituted compounds 百时美施贵宝公司 2023-01-20 CN disclosed
US-20210163465-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2021-06-03 US disclosed
US-20190292176-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BISTOL MYERS SQUIBB COMPANY (US) 2019-09-26 US disclosed
WO-2018013774-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2018-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190292176-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS F2, F2RL3, PF4 CYP3A4 15/4885MAOB 550/4885CA12 3728/4885
US-20210163465-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS F2, F2RL3, F12 CYP3A4 18/4885MAOB 507/4885CA12 3794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.